Table of Contents
Hepatitis Research and Treatment
Volume 2012 (2012), Article ID 520362, 5 pages
http://dx.doi.org/10.1155/2012/520362
Clinical Study

Hepatitis B Infection in Microbiology Laboratory Workers: Prevalence, Vaccination, and Immunity Status

1Department of Microbiology, Maulana Azad Medical College, University of Delhi, Bahadur Shah Zafar Marg, New Delhi 110002, India
2Central Surveillance Unit, Integrated Disease Surveillance Project (IDSP), National Center for Disease Control (NCDC), New Delhi 110054, India

Received 2 August 2012; Accepted 18 November 2012

Academic Editor: Piero Luigi Almasio

Copyright © 2012 Arun Kumar Jha et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The risk of contracting HBV by health care workers (HCW) is four-times greater than that of general adult population. Studies have demonstrated that vaccine-induced protection persists at least 11 years. High risk groups such as HCWs should be monitored and receive a booster vaccination if their anti-HBsAb levels decrease below 10 mIU/mL. In view of the above this study was undertaken to assess the HBV vaccination of the HCWs and their immunological response. Seventy-two HCWs of the Department of Microbiology, Maulana Azad Medical College, New Delhi, India, were recruited and blood sample was drawn for serological tests (HBSAg, anti-HCV, anti-HBsAb, anti-HBeAb, and anti-HBcAb). Anti-HBs titers of >10 mIU/mL were considered protective. Thirty-four (47.3%) of the participants were completely vaccinated with three doses. 25 (73.5%) of the participants with complete vaccination had protective anti-HBsAb levels as against 8 (53.3%) of those with incomplete vaccination and 9 (39.1%) of those who were not vaccinated at all. One of our participants was acutely infected while 29 participants were susceptible to infection at the time of the study. All HCWs should receive three doses of the vaccine and be monitored for their immune status after every five years. Boosters should be administered to those who become susceptible.